Ciblage thérapeutique personnalisé par analyse d'exomes = Personalized therapeutic targeting by exome analysisLAMY, Aude; ANGOT, Emilie; SABOURIN, Jean-Christophe et al.Annales de pathologie (Print). 2012, Vol 32, issn 0242-6498, S44-S45, HS1Conference Paper

Novel agents in the era of targeted therapy : what have we learned and how has our practice changed?BASELGA, J.Annals of oncology. 2008, Vol 19, issn 0923-7534, vii281-vii288, SUP7Article

Truncated HER2: implications for HER2-targeted therapeuticZAGOZDZON, Radoslaw; GALLAGHER, William M; CROWN, John et al.Drug discovery today. 2011, Vol 16, Num 17-18, pp 810-816, issn 1359-6446, 7 p.Article

Targeted Delivery of a Photosensitizer to Aggregatibacter actinomycetemcomitans BiofilmSUCI, Peter; KANG, Sebyung; GMÜR, Rudolf et al.Antimicrobial agents and chemotherapy. 2010, Vol 54, Num 6, pp 2489-2496, issn 0066-4804, 8 p.Article

Pharmacokinetic Considerations for New Targeted TherapiesBAKER, S. D; HU, S.Clinical pharmacology and therapeutics. 2009, Vol 85, Num 2, pp 208-211, issn 0009-9236, 4 p.Article

Discovery of Inhibitors of 4'-Phosphopantetheine Adenylyltransferase (PPAT) To Validate PPAT as a Target for Antibacterial TherapyDE JONGE, Boudewijn L. M; WALKUP, Grant K; JOHNSTONE, Michele et al.Antimicrobial agents and chemotherapy. 2013, Vol 57, Num 12, pp 6005-6015, issn 0066-4804, 11 p.Article

Nuclear transport : Target for therapyFAUSTINO, R. S; NELSON, T. J; TERZIC, A et al.Clinical pharmacology and therapeutics. 2007, Vol 81, Num 6, pp 880-886, issn 0009-9236, 7 p.Article

Targeted therapy for neuro-oncology : reviewing the menuLAMPSON, Lois A.Drug discovery today. 2009, Vol 14, Num 3-4, pp 185-191, issn 1359-6446, 7 p.Article

Preclinical Studies of Novel Targeted TherapiesHIDESHIMA, Teru; ANDERSON, Kenneth C.Hematology/oncology clinics of North America. 2007, Vol 21, Num 6, issn 0889-8588, viii-ix, 1071-1091 [22 p.]Article

The science of direct-acting antiviral and host-targeted agent therapyPAWLOTSKY, Jean-Michel.Antiviral therapy (London). 2012, Vol 17, Num 6, pp 1109-1117, issn 1359-6535, 9 p., bArticle

DNA Repair: A Reinvigorated Therapeutic TargetBATES, Susan E.Clinical cancer research (Print). 2010, Vol 16, Num 18, issn 1078-0432, p. 4510Article

Theileria Apicoplast as a Target for ChemotherapyLIZUNDIA, Regina; WERLING, Dirk; LANGSLEY, Gordon et al.Antimicrobial agents and chemotherapy. 2009, Vol 53, Num 3, pp 1213-1217, issn 0066-4804, 5 p.Article

RNA editing as a therapeutic target for CNS disordersMORABITO, Michael V; EMESON, Ronald B.Neuropsychopharmacology (New York, NY). 2009, Vol 34, Num 1, pp 246-246, issn 0893-133X, 1 p.Article

Src Kinase Is a Novel Therapeutic Target in LymphangioleiomyomatosisTYRYSHKIN, Alexey; BHATTACHARYA, Abhisek; EISSA, N. Tony et al.Cancer research (Chicago, Ill.). 2014, Vol 74, Num 7, pp 1996-2005, issn 0008-5472, 10 p.Article

Polycomb Repressor Complex-2 Is a Novel Target for Mesothelioma TherapyKEMP, Clinton D; RAO, Mahadev; ZHU, Yuelin J et al.Clinical cancer research (Print). 2012, Vol 18, Num 1, pp 77-90, issn 1078-0432, 14 p.Article

Intérêt des thérapies ciblées = Interest of targeted therapiesCOUSSY, Florence; ESPIE, Marc.La Lettre du gynécologue. 2012, Num 376, pp 22-26, issn 0759-1594, 5 p.Article

Targets for Current Pharmacologic Therapy in Cholesterol Gallstone DiseaseDI CIAULA, Agostino; WANG, David Q. H; WANG, Helen H et al.Gastroenterology clinics of North America. 2010, Vol 39, Num 2, issn 0889-8553, 245-264, viii-ix [22 p.]Article

Molecular Pathways: HER3 Targeted TherapyGALA, Kinisha; CHANDARLAPATY, Sarat.Clinical cancer research (Print). 2014, Vol 20, Num 6, pp 1410-1416, issn 1078-0432, 7 p.Article

Survival of 1,181 Patients in a Phase IClinic: The MD Anderson Clinical Center for Targeted Therapy ExperienceWHELER, Jennifer; TSIMBERIDOU, Apostolia M; KURZROCK, Razelle et al.Clinical cancer research (Print). 2012, Vol 18, Num 10, pp 2922-2929, issn 1078-0432, 8 p.Article

Basic and clinical interface in targeted cancer therapyBiomedicine & pharmacotherapy. 2008, Vol 62, Num 7, pp 421-429, issn 0753-3322, 8 p.Conference Paper

Twenty-fourth Annual Pezcoller Symposium: Molecular Basis for Resistance to Targeted AgentsMARAIS, Richard; SELLERS, William; LIVINGSTON, David et al.Cancer research (Chicago, Ill.). 2013, Vol 73, Num 3, pp 1046-1049, issn 0008-5472, 4 p.Article

COL4A1 and COL4A2 mutations and disease: insights into pathogenic mechanisms and potential therapeutic targetsKUO, Debbie S; LABELLE-DUMAIS, Cassandre; GOULD, Douglas B et al.Human molecular genetics (Print). 2012, Vol 21, Num 1, issn 0964-6906, R97-R110, NS1Article

Biologically Targeted Cancer Therapy and Marginal Benefits: Are We Making Too Much of Too Little or Are We Achieving Too Little by Giving Too Much? : Improving Outcomes in OncologyFOJO, Tito; PARKINSON, David R.Clinical cancer research (Print). 2010, Vol 16, Num 24, pp 5972-5980, issn 1078-0432, 9 p.Article

Prospects for TIM3-Targeted Antitumor ImmunotherapyNGIOW, Shin Foong; TENG, Michele W. L; SMYTH, Mark J et al.Cancer research (Chicago, Ill.). 2011, Vol 71, Num 21, pp 6567-6571, issn 0008-5472, 5 p.Article

Therapeutic Targeting of the DNA Mismatch Repair PathwayMARTIN, Sarah A; LORD, Christopher J; ASHWORTH, Alan et al.Clinical cancer research (Print). 2010, Vol 16, Num 21, pp 5107-5113, issn 1078-0432, 7 p.Article